Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study
Objective. To assess the impact of low-to-moderate risk prostate cancer on patients’ quality of life (QoL) at diagnosis and within the first year of treatment. Subjects and Methods. Men (n=672) aged 50–75 years with prostate cancer (Gleason score ≤7, PSA ≤20 ng/mL and clinical staging T1c–T2b) were...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Prostate Cancer |
| Online Access: | http://dx.doi.org/10.1155/2014/472949 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563466602283008 |
|---|---|
| author | Cesare Selli Anders Bjartell Javier Burgos Matthew Somerville Juan-Manuel Palacios Laure Benjamin Libby Black Ramiro Castro |
| author_facet | Cesare Selli Anders Bjartell Javier Burgos Matthew Somerville Juan-Manuel Palacios Laure Benjamin Libby Black Ramiro Castro |
| author_sort | Cesare Selli |
| collection | DOAJ |
| description | Objective. To assess the impact of low-to-moderate risk prostate cancer on patients’ quality of life (QoL) at diagnosis and within the first year of treatment. Subjects and Methods. Men (n=672) aged 50–75 years with prostate cancer (Gleason score ≤7, PSA ≤20 ng/mL and clinical staging T1c–T2b) were enrolled in five European countries. Patients completed five questionnaires, including EORTC Quality of Life Questionnaire—Prostate Cancer 25 (QLQ-PR25) and EORTC Quality of Life Questionnaire—Cancer 30 (QLQ-C30). Questionnaires were completed at baseline, at 3 months and 12 months after starting treatment. The primary endpoint was the change in QLQ-PR25 urinary symptoms subscale score from baseline to the assessment at 3 months. Results. Mean (SD) age was 65.0 (5.7) years and 400 (66%) men had Gleason score ≤6 prostate cancer. The most frequently used initial treatment was radical prostatectomy (71% of patients). QLQ-PR25 urinary symptoms subscale score was significantly increased at 3 months (P<0.001), indicating that urinary symptoms worsened after treatment. The score was lower at 12 months than at 3 months, but it was still significantly higher than at baseline (P<0.001). Hormonal treatment-related symptoms, sexual functioning, and sexual activity scores significantly worsened at 3 and 12 months (all P<0.001). For the QLQ-C30 questionnaire, global health status/QoL score significantly decreased at month 3 but was not different from baseline by month 12. Scales for physical, role, and social functioning, and fatigue, showed significant deterioration at 3 and 12 months. Conclusions. Low-to-moderate risk prostate cancer may have a substantial effect on patients’ QoL within one year following treatment. |
| format | Article |
| id | doaj-art-f1477c99e064491f9991f14b0f130454 |
| institution | Kabale University |
| issn | 2090-3111 2090-312X |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Prostate Cancer |
| spelling | doaj-art-f1477c99e064491f9991f14b0f1304542025-02-03T01:20:14ZengWileyProstate Cancer2090-31112090-312X2014-01-01201410.1155/2014/472949472949Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational StudyCesare Selli0Anders Bjartell1Javier Burgos2Matthew Somerville3Juan-Manuel Palacios4Laure Benjamin5Libby Black6Ramiro Castro7Department of Urology, University of Pisa, 56126 Pisa, ItalySkåne University Hospital, SE 205 02 Malmö, SwedenHospital Ramon y Cajal, 28034 Madrid, SpainGlaxoSmithKline, Research Triangle Park, NC 27709, USAGlaxoSmithKline, Urology Centre of Excellence, C/Severo Ochoa 2, Tres Cantos, 28760 Madrid, SpainGlaxoSmithKline, Health Outcomes Studies, 78160 Marly-Le-Roi, FranceGlaxoSmithKline, Research Triangle Park, NC 27709, USAGlaxoSmithKline, King of Prussia, PA 19406, USAObjective. To assess the impact of low-to-moderate risk prostate cancer on patients’ quality of life (QoL) at diagnosis and within the first year of treatment. Subjects and Methods. Men (n=672) aged 50–75 years with prostate cancer (Gleason score ≤7, PSA ≤20 ng/mL and clinical staging T1c–T2b) were enrolled in five European countries. Patients completed five questionnaires, including EORTC Quality of Life Questionnaire—Prostate Cancer 25 (QLQ-PR25) and EORTC Quality of Life Questionnaire—Cancer 30 (QLQ-C30). Questionnaires were completed at baseline, at 3 months and 12 months after starting treatment. The primary endpoint was the change in QLQ-PR25 urinary symptoms subscale score from baseline to the assessment at 3 months. Results. Mean (SD) age was 65.0 (5.7) years and 400 (66%) men had Gleason score ≤6 prostate cancer. The most frequently used initial treatment was radical prostatectomy (71% of patients). QLQ-PR25 urinary symptoms subscale score was significantly increased at 3 months (P<0.001), indicating that urinary symptoms worsened after treatment. The score was lower at 12 months than at 3 months, but it was still significantly higher than at baseline (P<0.001). Hormonal treatment-related symptoms, sexual functioning, and sexual activity scores significantly worsened at 3 and 12 months (all P<0.001). For the QLQ-C30 questionnaire, global health status/QoL score significantly decreased at month 3 but was not different from baseline by month 12. Scales for physical, role, and social functioning, and fatigue, showed significant deterioration at 3 and 12 months. Conclusions. Low-to-moderate risk prostate cancer may have a substantial effect on patients’ QoL within one year following treatment.http://dx.doi.org/10.1155/2014/472949 |
| spellingShingle | Cesare Selli Anders Bjartell Javier Burgos Matthew Somerville Juan-Manuel Palacios Laure Benjamin Libby Black Ramiro Castro Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study Prostate Cancer |
| title | Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study |
| title_full | Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study |
| title_fullStr | Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study |
| title_full_unstemmed | Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study |
| title_short | Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study |
| title_sort | burden of illness in prostate cancer patients with a low to moderate risk of progression a one year pan european observational study |
| url | http://dx.doi.org/10.1155/2014/472949 |
| work_keys_str_mv | AT cesareselli burdenofillnessinprostatecancerpatientswithalowtomoderateriskofprogressionaoneyearpaneuropeanobservationalstudy AT andersbjartell burdenofillnessinprostatecancerpatientswithalowtomoderateriskofprogressionaoneyearpaneuropeanobservationalstudy AT javierburgos burdenofillnessinprostatecancerpatientswithalowtomoderateriskofprogressionaoneyearpaneuropeanobservationalstudy AT matthewsomerville burdenofillnessinprostatecancerpatientswithalowtomoderateriskofprogressionaoneyearpaneuropeanobservationalstudy AT juanmanuelpalacios burdenofillnessinprostatecancerpatientswithalowtomoderateriskofprogressionaoneyearpaneuropeanobservationalstudy AT laurebenjamin burdenofillnessinprostatecancerpatientswithalowtomoderateriskofprogressionaoneyearpaneuropeanobservationalstudy AT libbyblack burdenofillnessinprostatecancerpatientswithalowtomoderateriskofprogressionaoneyearpaneuropeanobservationalstudy AT ramirocastro burdenofillnessinprostatecancerpatientswithalowtomoderateriskofprogressionaoneyearpaneuropeanobservationalstudy |